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incidence
The crude incidence and mortality of pancreatic cancer in the
European Union is 11/100 000/year. In 5% of patients some
genetic basis for the disease can be found.
diagnosis
Pathological diagnosis should be made according to the WHO
classification from a biopsy or fine needle aspiration. Ductal
adenocarcinomas constitute 95% of the epithelial tumors.
staging and risk assessment
Staging consists of complete history and physical examination,
blood counts, liver enzymes, chest X-ray, imaging of the
abdomen by sonography and CT scan or magnetic resonance,
and possibly by endosonography.
Patients with pancreatic cancer may be staged according to
the TNM system and can be grouped as shown in the table
below.
However, the distinction of whether or not a tumor remains
resectable is not well reflected in the TNM system, as
demonstrated by the wide range of survival figures given for
each stage.
Evaluation of resectability often requires surgery, preferably
by staging laparoscopy, to exclude clinically occult intra-
abdominal and lymph node metastases.
To be resectable, tumors must show no evidence of
extrapancreatic disease or direct tumor extension to the celiac
axis and superior mesenteric artery but evidence of non-
obstructive superior mesenteric–portal vein confluence does
not always preclude tumor resection.
Less than 20% of all patients have resectable disease.
treatment of resectable tumors
Complete surgical resection is the only potentially
curative treatment available. However, 5-year overall
survival is only 10–20%. Long-term survival in N+ tumors
is rare.
Preoperative or postoperative chemotherapy with or without
radiotherapy remains controversial.
treatment of locally advanced or
metastatic disease
Optimal symptomatic treatment has a prime role in the
management of metastatic disease. This may require stenting or
bypass surgery for obstructive jaundice or gastric outlet
obstruction.
The role of chemotherapy is limited. Gemcitabine has been
associated with a small survival benefit compared with bolus
5-fluorouracil [II, B].
response evaluation
Objective response evaluation by the initial radiographic
test may not be necessary for adequate patient
management. Evaluation of response should be symptom
driven.
follow-up
Due to the limited effectiveness of treatments follow-up after
complete resection should be restricted to history and
physical examination.
Stage Primary
tumor
Lymph
nodes
Distant
metastases
5-year
survival (%)
Stage 0 Tis N0 M0 –
Stage I T1–2 N0 M0 5–35
Stage II T3 N0 M0 2–15
Stage III T1–3 N1 M0 2–15
Stage IVA T4 Any N M0 1–5
Stage IVB Any T Any N M1 <1
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note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts and
the ESMO faculty.
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